Legacy Financial Advisors Inc. Buys 1,340 Shares of Elevance Health, Inc. $ELV

Legacy Financial Advisors Inc. boosted its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 54.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,816 shares of the company’s stock after buying an additional 1,340 shares during the quarter. Legacy Financial Advisors Inc.’s holdings in Elevance Health were worth $1,338,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. World Investment Advisors lifted its holdings in Elevance Health by 6.0% during the 4th quarter. World Investment Advisors now owns 28,290 shares of the company’s stock valued at $9,606,000 after buying an additional 1,597 shares in the last quarter. Englebert Financial Advisers LLC bought a new stake in Elevance Health during the 4th quarter valued at about $687,000. HighPoint Advisor Group LLC lifted its holdings in Elevance Health by 3.2% during the 4th quarter. HighPoint Advisor Group LLC now owns 4,685 shares of the company’s stock valued at $1,642,000 after buying an additional 144 shares in the last quarter. Money Concepts Capital Corp lifted its holdings in Elevance Health by 8.8% during the 4th quarter. Money Concepts Capital Corp now owns 2,904 shares of the company’s stock valued at $1,018,000 after buying an additional 235 shares in the last quarter. Finally, Bailard Inc. lifted its holdings in Elevance Health by 15.5% during the 4th quarter. Bailard Inc. now owns 4,717 shares of the company’s stock valued at $1,654,000 after buying an additional 632 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 3.0%

NYSE ELV opened at $393.12 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The company has a market capitalization of $85.37 billion, a price-to-earnings ratio of 16.72, a price-to-earnings-growth ratio of 2.17 and a beta of 0.66. The company’s 50-day simple moving average is $316.48 and its two-hundred day simple moving average is $332.85. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $412.96.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter last year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities analysts forecast that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a report on Tuesday, February 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Evercore lifted their price objective on shares of Elevance Health from $345.00 to $360.00 in a report on Thursday, April 23rd. Mizuho cut their target price on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Finally, Sanford C. Bernstein raised their target price on shares of Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research report on Friday, April 24th. Thirteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $384.58.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.